Serina Therapeutics, Inc.

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease